Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Jalap	NCIT_C73899
Drug, Natural Product	NCIT_C1907	[Any drug derived from microorganisms, plants, or animals; also, synthesized versions of these substances or their derivatives.]
Twenty Nine	NCIT_C105800	[A natural number greater than twenty-eight and less than thirty and the quantity that it denotes.]
Nineteen	NCIT_C105801	[A natural number greater than eighteen and less than twenty and the quantity that it denotes.]
Liposome-encapsulated miR-34 Mimic MRX34	NCIT_C105802	[A liposomal formulation containing a nucleotide that mimics the human tumor suppressor microRNA (miRNA) miR-34, with potential antineoplastic activity. Upon administration, liposome-encapsulated MRX34 mimics miR-34 by inhibiting the expression of a variety of oncogenes including MYC, MET, BCL2, and beta-catenin. This induces cell cycle arrest, senescence and apoptosis in susceptible tumor cells. miR-34 is downregulated in most solid and hematologic malignancies and regulates the expression of a variety of genes. This miRNA plays an important role in the inhibition of cancer cell stemness, metastasis and cancer cell survival.]
Anti-MMP-9 Monoclonal Antibody GS-5745	NCIT_C105803	[A humanized monoclonal antibody against matrix metalloproteinase 9 (MMP-9), with potential antineoplastic activity. Upon administration, anti-MMP-9 monoclonal antibody GS-5745 binds to MMP-9 and inhibits its enzymatic activity. This results in an inhibition of extracellular matrix protein degradation and, potentially, the inhibition of angiogenesis, tumor growth, invasion, and metastasis. MMP-9, a protein belonging to the MMP family, plays a key role in the degradation of collagens and proteoglycans; increased activity of MMP-9 has been associated with increased invasion and metastasis of cancer.]
Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate	NCIT_C105804	[The tosylate salt form of PLX7486, a selective inhibitor of the receptor tyrosine kinases colony-stimulating factor-1 receptor (CSF1R; fms) and neurotrophic tyrosine kinase receptor types 1, 2 and 3 (TrkA, TrkB, and TrkC, respectively) with potential antineoplastic activity. Upon administration, PLX7486 binds to and inhibits the activity of these tyrosine kinases. This inhibits Fms and Trk-mediated signaling transduction pathways that are upregulated in certain cancer cell types. This may eventually halt tumor cell proliferation in Fms and TrkA, TrkB, and/or TrkC-overexpressing tumor cells. Fms and TrkA, TrkB, and TrkC are receptor tyrosine kinases that are upregulated or mutated in a variety of tumors and promote tumor cell proliferation and survival.]
Anti-CD19 Monoclonal Antibody DI-B4	NCIT_C105805	[A low-fucosylated, humanized, IgG1 isotype, monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities. Anti-CD19 monoclonal antibody DI-B4 binds to CD19, which may result in a strong antibody-dependent cellular cytotoxicity (ADCC) directed at CD19-expressing B-cells but with minimal complement dependent cytotoxicity. DI-B4 contains low levels of fucose, which contributes to its enhanced ADCC activity. CD19 is a B-cell specific membrane antigen that is widely expressed during B-cell development and in all B-cell lineage malignancies.]
Autologous Sarcoma Lysate-pulsed Dendritic Cell Vaccine	NCIT_C105806	[A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from sarcoma cells with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous sarcoma lysate-pulsed dendritic cell vaccine exposes the immune system to an undefined amount of sarcoma-type tumor associated antigens (TAA), which may result in the induction of both specific anti-tumoral cytotoxic T lymphocytes (CTL) and antibody-dependent responses against the sarcoma TAA-expressing cells, resulting in sarcoma cell lysis.]
Autologous Sarcoma Cell Lysate	NCIT_C105807	[A cell lysate derived from sarcoma cells with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the autologous sarcoma cell lysate exposes the immune system to an undefined amount of sarcoma-type tumor associated antigens (TAA), which may result in the induction of both specific anti-tumoral cytotoxic T lymphocytes (CTL) and antibody-dependent responses against the sarcoma TAA-expressing cells, resulting in sarcoma cell lysis.]
Indium In 111 Pertuzumab	NCIT_C105808	[A radioimmunoconjugate composed of a humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the tyrosine kinase receptor human epidermal growth factor-2 (HER-2) and linked to the gamma-emitting radioisotope indium In 111, with potential use in radioimaging. Upon administration, indium In 111 pertuzumab binds to HER-2. After binding and internalization into HER-2-expressing tumor cells, radioactive In 111 facilitates the detection of HER-2-expressing tumor cells using single photon emission computed tomography (SPECT). This may predict or evaluate the tumor's response to certain HER-2-targeting chemotherapeutics.]
AdGMCAIX-transduced Autologous Dendritic Cells	NCIT_C105809	[Autologous dendritic cells (DCs) transduced with a recombinant, replication-defective adenoviral vector expressing the fusion gene granulocyte-macrophage colony-stimulating factor (GM-CSF) and carbonic anhydrase IX (CA-IX or CA9) (GMCA-9), with potential immunomodulating activity. The autologous DCs are transduced ex vivo and express the GMCA-9 fusion protein on the cell surface. Upon intradermal administration of the AdGMCAIX-transduced autologous DCs back into the patient, the DCs activate the immune system to both mount a cytotoxic T lymphocyte-mediated response against tumor cells positive for the CA9 antigen, and generate memory T cells. This may result in decreased tumor growth. CA9, also known as G250, is a renal cell carcinoma (RCC)-associated antigen and a member of the carbonic anhydrase family that contains a human leukocyte antigen (HLA)-A2.1-restricted epitope; it is found in a majority of renal cell carcinomas while absent in most normal tissues. The cytokine GM-CSF enhances the immunogenicity of CA9-based DC vaccines.]
WHODAS 2.0 36-item Version Interviewer-administered - Getting Household Work Done Quickly	NCIT_C130750	[World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Getting your household work done as quickly as needed?]
WHODAS 2.0 36-item Version Interviewer-administered Questionnaire Question	NCIT_C130297	[A question associated with the WHODAS 2.0 36-item Version Interviewer-administered questionnaire.]
Fifty Nine	NCIT_C105794	[A natural number greater than fifty-eight and less than sixty and the quantity that it denotes.]
Tertiary Chorionic Villus	NCIT_C34310	[A stage in the development of the chorionic villi that occurs at approximately 21 days gestation, and which is characterized by the vascularization of the chorionic villi.]
WHODAS 2.0 36-item Version Interviewer-administered - Days Reduce or Miss Household Work	NCIT_C130751	[World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, on how many days did you reduce or completely miss household work because of your health condition?]
Forty	NCIT_C105795	[A natural number greater than thirty-nine and less than forty-one and the quantity that it denotes.]
Third Pharyngeal Pouch	NCIT_C34311	[A paired evagination of embryonic pharyngeal endoderm located between pharyngeal arches three and four, which contributes to the formation of both the inferior parathyroid gland and the thymus gland.]
WHODAS 2.0 36-item Version Interviewer-administered - Your Day-to-Day Work or School	NCIT_C130752	[World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Your day-to-day work/school?]